



OUTSOURCING

The Top 10 Contract Research Organizations

Positioning, performance and SWOT analyses

 [Table of Contents](#)

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any
purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of
Business Insights. Business Insights Ltd accepts no liability for the accuracy or
completeness of the information, advice or comment contained in this Management
Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of
publication, no responsibility can be accepted by Business Insights Ltd for its
completeness or accuracy.

Table of Contents

The Top 10 Contract Research Organizations

| | |
|---|-----------|
| Executive summary | 14 |
| Industry overview | 14 |
| Quintiles | 15 |
| Covance | 15 |
| Pharmaceutical Product Development (PPD) | 16 |
| Charles River Laboratories (CRL) | 16 |
| ICON Clinical (ICON) | 17 |
| Parexel | 17 |
| MDS | 18 |
| Kendle | 18 |
| PharmaNet Development (PharmaNet) | 19 |
| PRA International | 19 |
| | |
| Chapter 1 Introduction | 22 |
| What is this report about? | 22 |
| Methodology | 22 |
| | |
| Chapter 2 Industry overview | 24 |
| Summary | 24 |
| Introduction | 25 |
| Market overview | 25 |
| Global CRO market: size and growth | 25 |
| Global positioning of the top 10 CROs | 26 |
| Key market drivers | 29 |
| Key market resistors | 30 |
| Business models | 31 |

| | |
|---|-----------|
| Full-services CROs | 31 |
| Niche CROs | 31 |
| Trends in the global CRO industry | 32 |
| Consolidation in the CRO industry | 32 |
| Evolution of software as a service (SaaS) based electronic data capture (EDC) | 35 |
| Implementation of biomarkers in clinical trials | 36 |
| Participation of private equity players | 38 |
| New CRO destinations | 39 |
| Asia-Pacific | 39 |
| India | 39 |
| China | 40 |
| Latin America | 42 |
| Eastern Europe | 42 |
| Africa | 43 |

Chapter 3 Quintiles 46

| | |
|--|-----------|
| Summary | 46 |
| Company overview | 47 |
| Recent financial performance | 48 |
| Growth strategies | 48 |
| Investing in infrastructure | 48 |
| Expansion of consulting business | 50 |
| Acquisitions and divestments | 50 |
| SWOT analysis | 51 |
| Strengths | 52 |
| Depth in service offerings | 52 |
| Strong presence in emerging economies | 52 |
| Weaknesses | 53 |
| Exposure in limited therapeutic areas | 53 |
| Opportunities | 53 |
| Launch of interactive data analysis tool | 53 |
| New facility in India | 53 |
| Expansion in Japan | 53 |
| Threats | 54 |
| Stringent regulations | 54 |
| Increasing competition | 55 |

Chapter 4 Covance 58

| | |
|-------------------------------------|-----------|
| Summary | 58 |
| Company overview | 59 |
| Recent financial performance | 59 |

| | |
|---|-----------|
| Performance by business segment | 61 |
| Growth strategies | 61 |
| Attaining operational efficiency through six sigma implementation | 61 |
| Develop capabilities in emerging markets | 62 |
| Acquisitions and divestments | 62 |
| SWOT analysis | 63 |
| Strengths | 63 |
| Global capabilities | 63 |
| Stronger therapeutic base | 64 |
| Strong liquidity position | 64 |
| Weaknesses | 64 |
| Declining performance in late-stage segment | 64 |
| Opportunities | 65 |
| Expanding facilities in mature pharmaceutical markets | 65 |
| R&D collaboration with Eli Lilly | 65 |
| Threats | 66 |
| Weakening early-stage development segment | 66 |
| Regulatory compliance | 66 |

Chapter 5 Pharmaceutical Product Development 68

| | |
|---|-----------|
| Summary | 68 |
| Company overview | 69 |
| Recent financial performance | 69 |
| Performance by business segment | 70 |
| Growth strategies | 71 |
| Collaboration for development of innovative compounds | 71 |
| Expansion in central laboratory services | 71 |
| Acquisitions and divestments | 72 |
| SWOT analysis | 73 |
| Strengths | 74 |
| Depth in phase II–IV service offering | 74 |
| Strong financial performance | 74 |
| Weaknesses | 74 |
| Declining revenue contribution from PPD’s discovery segment | 74 |
| Opportunities | 75 |
| Investment in technologies | 75 |
| Geographical expansion | 75 |
| Outsourcing deal with Merck | 76 |
| Threats | 76 |
| Dependence on a small number of industries and clients | 76 |

Chapter 6 Charles River Laboratories 78

| | | |
|-------------------------------------|--|-----------|
| Summary | | 78 |
| Company overview | | 79 |
| Recent financial performance | | 79 |
| Performance by business segment | | 80 |
| Growth strategies | | 81 |
| Building capabilities for clients | | 81 |
| Acquisitions and divestments | | 81 |
| SWOT analysis | | 82 |
| Strengths | | 83 |
| | Strong technology platforms for pre-clinical testing | 83 |
| Weaknesses | | 83 |
| | Higher debt burden | 83 |
| Opportunities | | 84 |
| | Expansion in China | 84 |
| Threats | | 84 |
| | Cost cutting in biopharmaceutical industry | 84 |

Chapter 7 ICON 86

| | | |
|--|--|-----------|
| Summary | | 86 |
| Company overview | | 87 |
| Recent financial performance | | 87 |
| Performance by business segments | | 88 |
| Growth strategies | | 88 |
| Developing global capabilities and reach | | 88 |
| Acquisitions and divestments | | 89 |
| SWOT analysis | | 90 |
| Strengths | | 90 |
| | Strong presence in oncology solutions | 90 |
| | Technically enhanced service offerings | 91 |
| | Unconventional service model | 91 |
| Weaknesses | | 92 |
| | Rising debt load | 92 |
| Opportunities | | 92 |
| | Expansion in India | 92 |
| | Agreement with Phase Forward | 92 |
| Threats | | 93 |
| | Government regulations | 93 |
| | Softness in non-Critical Path studies | 93 |

Chapter 8 Parexel 96

| | | |
|-------------------------------------|--|-----|
| Summary | 96 | |
| Company overview | 97 | |
| Recent financial performance | 97 | |
| Performance by business segments | 98 | |
| Growth strategies | 99 | |
| Expansion in emerging markets | 99 | |
| Acquisitions and divestments | 100 | |
| SWOT analysis | 101 | |
| Strengths | 101 | |
| | Strong global presence | 101 |
| | Stronger therapeutic presence | 102 |
| Weaknesses | | 102 |
| | Increased receivable turnover period | 102 |
| Opportunities | | 102 |
| | Expansion in early-phase service offerings | 102 |
| Threats | | 103 |
| | Consolidation in the industry | 103 |
| | Declining R&D spending growth | 103 |

Chapter 9 MDS 106

| | | |
|---|---|-----|
| Summary | 106 | |
| Company overview | 107 | |
| Recent financial performance | 107 | |
| Performance by business segment | 109 | |
| Growth strategies | 109 | |
| Internal restructuring | 109 | |
| Investment in infrastructure across geographies | 110 | |
| Acquisitions and divestments | 110 | |
| SWOT analysis | 111 | |
| Strengths | 111 | |
| | Robust performance of late-stage contract research services | 111 |
| Weaknesses | | 112 |
| | Limited therapeutic focus | 112 |
| Opportunities | | 112 |
| | Investment in technology | 112 |
| | Expansion in Asian markets | 113 |
| Threats | | 113 |
| | Regulatory review | 113 |

| | |
|------------------------------|-----|
| Refinancing convertible debt | 134 |
| Government regulations | 134 |

Chapter 12 PRA International 136

| | | |
|---------------------------------------|--|-----|
| Summary | 136 | |
| Company overview | 137 | |
| Recent financial performance | 137 | |
| Growth strategies | 138 | |
| Capacity expansion across geographies | 138 | |
| Increased prominence in oncology | 139 | |
| Acquisitions and divestments | 139 | |
| SWOT analysis | 140 | |
| Strengths | 140 | |
| | Services portfolio | 140 |
| Weaknesses | 141 | |
| | Limited therapeutic expertise | 141 |
| | Lower sales growth during 2004–07 | 141 |
| Opportunities | 141 | |
| | Collaboration with Frontage Laboratories | 141 |
| | Growing opportunities in India | 142 |
| Threats | 142 | |
| | Intense competition | 142 |
| | Regulatory compliance | 143 |

Chapter 13 Other key players 146

| | |
|-------------------------------|------------|
| Aptuit | 146 |
| Company overview | 146 |
| Recent financial performance | 146 |
| Life Sciences Research | 147 |
| Company overview | 147 |
| Recent financial performance | 147 |
| Omnicare | 149 |
| Company overview | 149 |
| Recent financial performance | 149 |
| SGS | 151 |
| Company overview | 151 |
| Recent financial performance | 151 |
| CMIC | 153 |
| Company overview | 153 |
| Recent financial performance | 153 |
| WuXi Pharmatech | 155 |

| | |
|------------------------------|------------|
| Company overview | 155 |
| Recent financial performance | 155 |
| Galapagos (BioFocus) | 157 |
| Company overview | 157 |
| Recent financial performance | 157 |
| LAB Research | 159 |
| Company overview | 159 |
| Recent financial performance | 159 |
| United BioSource | 161 |
| Company overview | 161 |
| Recent financial performance | 161 |
| Bio-Imaging | 162 |
| Company overview | 162 |
| Recent financial performance | 162 |

Chapter 14 Appendix 166

| | |
|-----------------|------------|
| Glossary | 166 |
| Index | 168 |

List of Figures

| | | |
|---------------|--|-----|
| Figure 2.1: | Global CRO market size (\$bn), 2008–13 | 26 |
| Figure 2.2: | Top 10 CRO companies market share (%), 2007 | 27 |
| Figure 2.3: | Market position of the global top 10 CROs, 2007 | 28 |
| Figure 2.4: | Comparative analysis of leading CRO companies | 29 |
| Figure 2.5: | Comparison between India and China CROs | 41 |
| Figure 3.6: | Quintiles SWOT analysis | 51 |
| Figure 4.7: | Covance financial performance (\$m), 2003–07 | 60 |
| Figure 4.8: | Covance SWOT analysis | 63 |
| Figure 5.9: | PPD financial performance (\$m), 2003–07 | 70 |
| Figure 5.10: | PPD SWOT analysis | 73 |
| Figure 6.11: | CRL financial performance (\$m), 2004–07 | 80 |
| Figure 6.12: | CRL SWOT analysis | 82 |
| Figure 7.13: | ICON SWOT analysis | 90 |
| Figure 8.14: | Parexel financial performance (\$m), 2004–08 | 98 |
| Figure 8.15: | Parexel SWOT analysis | 101 |
| Figure 9.16: | MDS financial performance (\$m), 2005–07 | 108 |
| Figure 9.17: | MDS SWOT analysis | 111 |
| Figure 10.18: | Kendle financial performance (\$m), 2003–07 | 118 |
| Figure 10.19: | Kendle SWOT analysis | 121 |
| Figure 11.20: | PharmaNet financial performance (\$m), 2004–07 | 128 |
| Figure 11.21: | PharmaNet SWOT analysis | 131 |
| Figure 12.22: | PRA International financial performance (\$m), 2003–07 | 138 |

| | | |
|---------------|--|-----|
| Figure 12.23: | PRA International SWOT analysis | 140 |
| Figure 13.24: | LSR financial performance (\$m), 2003–07 | 148 |
| Figure 13.25: | Omnicare financial performance (\$m), 2003–07 | 150 |
| Figure 13.26: | SGS financial performance (\$m), 2003–07 | 152 |
| Figure 13.27: | CMIC financial performance (\$m), 2005–08 | 154 |
| Figure 13.28: | WuXi Pharmatech financial performance (\$m), 2003–07 | 156 |
| Figure 13.29: | BioFocus financial performance (\$m), 2005–07 | 158 |
| Figure 13.30: | Lab Research financial performance (\$m), 2005–07 | 160 |
| Figure 13.31: | Bio-Imaging financial performance (\$m), 2003–07 | 163 |

List of Tables

| | | |
|--------------|--|-----|
| Table 2.1: | Global CRO market size (\$bn), 2008–13 | 26 |
| Table 2.2: | Select M&A deals in CRO industry 2007–08 | 32 |
| Table 2.3: | Select private equity deals in CRO industry (\$m), 2007–08 | 38 |
| Table 3.4: | Quintiles snapshot | 46 |
| Table 3.5: | Quintiles financial performance (\$m), 2003–07 | 48 |
| Table 4.6: | Covance snapshot | 58 |
| Table 4.7: | Covance financial performance (\$m), 2003–07 | 59 |
| Table 4.8: | Covance business segment performance, 2007 | 61 |
| Table 5.9: | PPD snapshot | 68 |
| Table 5.10: | PPD financial performance (\$m), 2003–07 | 69 |
| Table 5.11: | PPD business segment performance, 2007 | 70 |
| Table 6.12: | CRL snapshot | 78 |
| Table 6.13: | CRL financial performance (\$m), 2004–07 | 79 |
| Table 6.14: | CRL business segment performance, 2007 | 80 |
| Table 7.15: | ICON snapshot | 86 |
| Table 7.16: | ICON financial performance (\$m), 2003–07 | 87 |
| Table 7.17: | ICON business segment performance, 2007 | 88 |
| Table 8.18: | Parexel snapshot | 96 |
| Table 8.19: | Parexel financial performance (\$m), 2004–08 | 97 |
| Table 8.20: | Parexel business segment performance, 2008 | 99 |
| Table 9.21: | MDS snapshot | 106 |
| Table 9.22: | MDS financial performance (\$m), 2005–07 | 108 |
| Table 9.23: | MDS business segment performance, 2007 | 109 |
| Table 10.24: | Kendle snapshot | 116 |
| Table 10.25: | Kendle financial performance (\$m), 2003–07 | 117 |
| Table 10.26: | Kendle business segment performance, 2007 | 119 |
| Table 11.27: | PharmaNet snapshot | 126 |
| Table 11.28: | PharmaNet financial performance (\$m), 2004–07 | 128 |
| Table 11.29: | PharmaNet business segment performance, 2007 | 129 |
| Table 12.30: | PRA International snapshot | 136 |
| Table 12.31: | PRA International financial performance (\$m), 2003–07 | 137 |
| Table 13.32: | Aptuit Snapshot | 146 |
| Table 13.33: | LSR Snapshot | 147 |
| Table 13.34: | LSR financial performance (\$m), 2003–07 | 148 |
| Table 13.35: | Omnicare Snapshot | 149 |
| Table 13.36: | Omnicare financial performance (\$m), 2003–07 | 150 |

| | | |
|--------------|--|-----|
| Table 13.37: | SGS Snapshot | 151 |
| Table 13.38: | SGS financial performance (\$m), 2003–07 | 152 |
| Table 13.39: | CMIC Snapshot | 153 |
| Table 13.40: | CMIC financial performance (\$m), 2005–08 | 154 |
| Table 13.41: | WuXi Pharmatech Snapshot | 155 |
| Table 13.42: | WuXi Pharmatech financial performance (\$m), 2003–07 | 156 |
| Table 13.43: | BioFocus Snapshot | 157 |
| Table 13.44: | BioFocus financial performance (\$m), 2005–07 | 158 |
| Table 13.45: | LAB Research Snapshot | 159 |
| Table 13.46: | LAB Research financial performance (\$m), 2005–07 | 160 |
| Table 13.47: | UBC Snapshot | 161 |
| Table 13.48: | Bio-Imaging Snapshot | 162 |
| Table 13.49: | Bio-Imaging financial performance (\$m), 2003–07 | 163 |